Investor Presentaiton

Management Commentary We are on the cusp of long term growth across regulated markets. Our diversified portfolio continues to gain market share in these markets and helped us register growth, despite pricing and demand challenges. The geopolitical environment has impacted profitability, but we remain focused on our target to reach Rs 2,000 crores revenues along with margin improvement over the next couple of years. " 1,072.8 + 2.6% (YoY) Revenue 9MY22 (*cr.) ©2021 - Marksans Pharma Limited, All Rights Reserved. Mark Saldanha Founder, Chairman & Managing Director 195.2 (20.1)% (YoY) EBITDA 9MFY22 (*cr.) 157.2 (1.2)% (YoY) 9MFY22 PAT (cr.) 323.0 (Dec'21) Cash (cr.) 4

View entire presentation